(SACRAMENTO, Calif.) – Experts from UC Davis Health System will share the latest research about regenerative medicine, with a focus on chronic pain and the promise of stem cell therapies, during a community forum on the university's Sacramento campus. The discussion takes place on Tuesday, Feb. 7, from 6- 7:30 p.m. at the UC Davis Education Building, 4610 X Street, in Sacramento.

The event features Jan Nolta, director of the UC Davis Institute for Regenerative Cures; Scott Fishman, chief of the UC Davis Division of Pain Medicine; and Kee Kim, chief of spinal neurosurgery at UC Davis Medical Center. The three specialists will discuss the challenges of treating chronic pain, especially back and neck pain, and the clinical research now under way to use stem cell therapies to overcome it.

The forum is free and open to the public. It is part of “Stem Cell Dialogues,” UC Davis Health System's discussion series about regenerative medicine and the goal of turning stem cells into cures. Each speaker will provide a short presentation followed by a panel discussion and question and answer period. The event will be moderated by Fred Meyers, professor of medicine and pathology, and executive associate dean of UC Davis School of Medicine.

Seating is limited. Those interested in attending must reserve a seat by contacting Kate Rodrigues at 916-734-9404 or e-mail kathleen.rodrigues@ucdmc.ucdavis.edu. Doors open at 5:30 p.m.  Free parking will be available in Lots 12 and 14, just south of the Education Building, near 45th Street and 2nd Avenue.

UC Davis is playing a leading role in regenerative medicine, with nearly 150 scientists working on a variety of stem cell-related research projects at campus locations in both Davis and Sacramento. The UC Davis Institute for Regenerative Cures, a facility supported by the California Institute for Regenerative Medicine (CIRM), opened in 2010 on the Sacramento campus. This $62 million facility is the university's hub for stem cell science. It includes Northern California's largest academic Good Manufacturing Practice laboratory, with state-of-the-art equipment and manufacturing rooms for cellular and gene therapies. UC Davis also has a Translational Human Embryonic Stem Cell Shared Research Facility in Davis and a collaborative partnership with the Institute for Pediatric Regenerative Medicine at Shriners Hospital for Children Northern California. All of the programs and facilities complement the university's Clinical and Translational Science Center, and focus on turning stem cells into cures. For more information, visit www.ucdmc.ucdavis.edu/stemcellresearch.

Continued here:
The promise of stem cell therapies forum

View original post here:
Histogenics Corporation to Present at Canaccord Genuity Musculoskeletal Conference

www.youtube.com/watch?v=HMAbzHj2g9M

See the article here:
Dr Aziz Denian Transcranial Magnetic Stimulation 2011 ForVideoRecordShrinked2 pptx – Video

Excerpt from:
Kensey Nash Reports Second Quarter Fiscal Year 2012 Financial Results

www.youtube.com/watch?v=VsRhKZitpqQ

View original post here:
Mark Walter, MD introduces Prolotherapy and PRP: The New Field of Regenerative Medicine – Video

Read more:
Coronado Biosciences to attend the Alliance for Regenerative Medicine Biotech conference in San Francisco

www.youtube.com/watch?v=Bsc3newjNVc

Visit link:
2011 Summit: Keynote Address, CIRM’s Translational Roadmap to Stem Cell Cures, Alan Trounson, PhD – Video

MARLBOROUGH, Mass.–(BUSINESS WIRE)– Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Aberdeen Royal Infirmary, the largest of the Grampian University Hospitals in Scotland, has been confirmed as a site for its Phase 1/2 human clinical trial for Stargardt’s Macular Dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The Phase 1/2 trial is a prospective, open-label study designed to determine the safety and tolerability of the RPE cells following sub-retinal transplantation into patients with SMD.

“A leading medical institution in the United Kingdom, Aberdeen Royal Infirmary is an ideal partner for our European clinical trial for SMD,” said Gary Rabin, chairman and CEO of ACT. “Moreover, we are particularly pleased that the lead investigator is Dr. Noemi Lois, a leading expert in SMD. We continue to forge ties with some of the best eye surgeons and hospitals in the world and work towards bringing this cutting-edge therapy closer to fruition. Our preliminary results to date keep us optimistic that we are on the right path both in terms of our science and the clinical team we are working with, particularly eye surgeons such as Dr. Lois.”

Stargardt's Macular Dystrophy affects an estimated 80,000 to 100,000 patients in the U.S. and Europe, and causes progressive vision loss, usually starting in people between the ages of 10 to 20, although the disease onset can occur at any age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, the retinal pigment epithelium. “The first Stargardt’s patient to be treated in the U.S. with stem cell-derived RPE cells was a patient who was already legally blind as a consequence of this disease” stated Dr. Robert Lanza M.D., the chief scientific officer at ACT. Preliminary results from the treatment of the first SMD patient were recently reported in The Lancet (23 January 2012) and have been characterized by experts in the field of regenerative medicine as providing early signs of safety and efficacy.

This approved SMD clinical trial that Dr. Lois and her team will participate in is a prospective, open-label study designed to determine the safety and tolerability of RPE cells derived from hESCs following sub-retinal transplantation to patients with advanced SMD, and is similar in design to the FDA-cleared US trial initiated in July 2011.

“It is an honor to have been designated as a site for this path-breaking clinical trial,” said Noemi Lois, M.D., Ph.D. “We could not be more pleased to be a part of this trial for a promising potential new treatment for SMD, using hESC-derived RPE cells.” Dr. Lois is a is a member of the Department of Ophthalmology, NHS Grampian, and associated to the University of Aberdeen, Scotland, United Kingdom. Dr. Lois practices at the Aberdeen Royal Infirmary; she is an Ophthalmologist with special interest in Medical retina and Retinal surgery.

On January 23, 2012, the company announced that the first patient in this SMD clinical trial in Europe had been treated at Moorfields Eye Hospital in London.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2010. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.

The rest is here:
ACT Announces Aberdeen Royal Infirmary in Scotland as Additional Site for Phase 1/2 Clinical Trial Using hESC-Derived …

"http://www.medcitynews.com/2012/01/stem-cell-therapy-company-juventas-encouraged-by-heart-failure-trial/stem-cells/"
rel="attachment wp-att-119721"> "aligncenter size-full wp-image-119721" title="stem cells" src=
"http://www.medcitynews.com/wordpress/wp-content/uploads/stem-cells.jpg"
alt="" width="375" height="500">

Regenerative medicine company "http://www.medcitynews.com/tag/juventas-therapeutics/" style=
"color: inherit; text-decoration: none;" name=
"readabilityLink-1" id="readabilityLink-1">Juventas
Therapeutics "readability-DoNotFootnote" style=
"color: inherit;">^[1] is touting
the results from 12-month data of a phase 1 clinical trial of
heart failure patients.

At 12 months, heart failure patients treated with the company’s
stem cell therapy showed “significant” improvements in two key
measures — a six-minute distance-walking test, as well as the
"http://qol.thoracic.org/sections/instruments/ko/pages/mlwhfq.html"
onclick=
"javascript:_gaq.push(['_trackEvent','outbound-article','http://qol.thoracic.org']);"
style="color: inherit; text-decoration: none;" name=
"readabilityLink-2" id="readabilityLink-2">Minnesota Living
with Heart Failure Questionnaire "#readabilityFootnoteLink-2" class="readability-DoNotFootnote"
style="color: inherit;">^[2], a
patient self-assessment of how heart failure affects daily
life.

"http://www.clevelandplayhouse.com/main-stage/ten-chimneys"
onclick=
"javascript:_gaq.push(['_trackEvent','outbound-article','http://www.clevelandplayhouse.com']);"
target="_blank"> "http://www.medcitynews.com/wordpress/wp-content/uploads/CPH_TenChimneys.jpg"
alt="CPH Ten Chimneys">

Advertisement

"color: inherit; text-decoration: none;" name="readabilityLink-3"
id="readabilityLink-3">Dr. Marc Penn "#readabilityFootnoteLink-3" class="readability-DoNotFootnote"
style="color: inherit;">^[3],
Juventas’ founder and chief medical officer, said the results of
the trial suggest the company’s therapy is “inducing fundamental
changes in the heart of treated patients,” according to a
statement from Cleveland-based Juventas.

The company’s technology, "http://www.juventasinc.com/trials/index.html" onclick=
"javascript:_gaq.push(['_trackEvent','outbound-article','http://www.juventasinc.com']);"
style="color: inherit; text-decoration: none;" name=
"readabilityLink-4" id="readabilityLink-4">JVS-100 "#readabilityFootnoteLink-4" class="readability-DoNotFootnote"
style="color: inherit;">^[4],
works by recruiting stem cells from the bone marrow to create
new blood vessels and prevent ongoing cell death at the site of
a patient’s injury.

Juventas has plans in the works for two phase 2 clinical
trials. It’s preparing to enroll heart failure patients in a
trial that it hopes further illustrates the efficacy of its
technology. In addition, Juventas has already begun enrollment
in a phase 2a trial that will assess the safety and efficacy of
JVS-100 in onclick=
"javascript:_gaq.push(['_trackEvent','outbound-article','http://www.vdf.org']);"
style="color: inherit; text-decoration: none;" name=
"readabilityLink-5" id="readabilityLink-5">critical limb
ischemia "readability-DoNotFootnote" style=
"color: inherit;">^[5] patients.

Another Cleveland company founded by Penn, "http://www.medcitynews.com/tag/sironrx/" style=
"color: inherit; text-decoration: none;" name=
"readabilityLink-6" id="readabilityLink-6">SironRX
Therapeutics "readability-DoNotFootnote" style=
"color: inherit;">^[6], is
developing the JVS-100 technology for a different application:
wound healing. The two companies share the same CEO, Rahul
Aras.

[Photo from flickr user "http://www.flickr.com/photos/63475898@N02/" onclick=
"javascript:_gaq.push(['_trackEvent','outbound-article','http://www.flickr.com']);”
style=”color: inherit; text-decoration: none;” name=
“readabilityLink-7″ id=
“readabilityLink-7″>kurtislizaandchauncey "#readabilityFootnoteLink-7" class="readability-DoNotFootnote"
style="color: inherit;">^[7]]

Read the rest here:
Regenerative medicine company encouraged by heart failure trial

Go here to read the rest:
ACT Announces that Additional Patient with Stargardt’s Disease Has Undergone Embryonic Stem Cell Transplantation at …

www.youtube.com/watch?v=5vI9otTJhCM

See more here:
Bio-Dundee Conference 2011 – Regenerative Medicine – Video

View post:
Regenerative medicine firm KeraNetics closes in on $7M in financing

www.youtube.com/watch?v=WR4qZ1EO0nI

Go here to read the rest:
Center for Preventative and Regenerative Medicine – Video

Excerpt from:
Regenerative medicine firm TAPs Cambridge expertise

Read more from the original source:
Regenerative medicine for lung disease focus of $2.5 million Penn grant

View original post here:
SpineSmith Adds Talented Scientist to Research and Development Team

See the article here:
Leading Eye Institute to Participate in ACT’s Embryonic Stem Cell Clinical Trial for Macular Degeneration

Read the original:
Avance Nerve Graft Clinical Results Published

www.youtube.com/watch?v=doWpeZQ0a2k

Follow this link:
How It’s Made Season 17, Episode 1 Decorative Sombreros, Salad Dressings, Cap Guns, Regenerative Medicine – Video

View original post here:
Regenerative Medicine for Pets has Changed for the Better! Now Available “OsteoBioScaff™”